Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Albelda (Philadelphia, United States of America). Immunology-based therapeutic strategies in lung cancer and mesothelioma. International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology

Member's Comments

No comment yet.

Related content which might interest you: Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 The primary prevention of lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Bronchoscopic intratumoural therapies for non-small cell lung cancer Source: Eur Respir Rev, 29 (156) 200028; 10.1183/16000617.0028-2020 Year: 2020 Towards personalized treatment in non-small-cell lung carcinoma Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Venothromboembolism in lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 601s Year: 2007 Aerosoltherapy in lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008